All Stories

  1. A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex
  2. Careful classification of potential bedaquiline resistance mutations is critical when analysing their clinical impact
  3. Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis
  4. The exceptions that prove the rule—a historical view of bedaquiline susceptibility
  5. Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study
  6. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach
  7. Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis
  8. The small non-coding RNA B11 regulates multiple facets of Mycobacterium abscessus virulence
  9. Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis
  10. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
  11. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
  12. Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres
  13. Designing molecular diagnostics for current tuberculosis drug regimens
  14. Transcriptional regulation and drug resistance in Mycobacterium tuberculosis
  15. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
  16. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
  17. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
  18. Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex
  19. Making IGRA testing easier: First performance report of QIAreach QFT for tuberculosis infection diagnosis
  20. Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
  21. A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression
  22. A New Model of Chronic Mycobacterium abscessus Lung Infection in Immunocompetent Mice
  23. How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
  24. Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests
  25. Whole genome sequencing in Mycobacterium tuberculosis
  26. Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations
  27. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues
  28. Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex
  29. Evolution of programmatic definitions used in tuberculosis prevention and care
  30. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase
  31. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
  32. Drug resistance mechanisms and drug susceptibility testing for tuberculosis
  33. Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis
  34. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
  35. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
  36. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment
  37. Evolution of Phenotypic and Molecular Drug Susceptibility Testing
  38. Reaching consensus on drug resistance conferring mutations
  39. Reaching consensus on drug resistance conferring mutations
  40. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives
  41. Accelerating tuberculosis elimination in low-incidence settings: the role of genomics
  42. Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform: Figure 1.
  43. Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis
  44. Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRslAssay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study
  45. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data
  46. Drug Resistance in Mycobacterium tuberculosis
  47. Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis
  48. MicroRNA induction in human macrophages associated with infection with ancient and modern TB strains
  49. Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease
  50. Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
  51. Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
  52. miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis
  53. The roles of microRNAs on tuberculosis infection: Meaning or myth?
  54. Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis
  55. Mycobacterium tuberculosis Beijing Genotype Is Associated with HIV Infection in Mozambique
  56. Genome-Wide Discovery of Small RNAs in Mycobacterium tuberculosis
  57. Early tuberculosis treatment monitoring by Xpert® MTB/RIF: Figure 1–
  58. A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis
  59. GenoType MTBDRslperformance on clinical samples with diverse genetic background
  60. Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey
  61. Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?
  62. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique
  63. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso
  64. Identificazione molecolare di mutazioni conferenti resistenza a rifampicina ed isoniazide in M. tuberculosis in campioni clinici diretti mediante Genotype MTBDR (Hain Lifescience)
  65. Genotype MTBDRplus: a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis
  66. Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy